Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).-Reference-Cited by-同舟云学术

Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).

Published:2016-05-20 Issue:15_suppl Volume:34 Page:9003-9003
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ahn Myung-Ju¹,Kim Dong-Wan²,Kim Tae Min³,Lin Chia-Chi⁴,Ratnayake Jayantha⁵,Carlie David J⁶,Yin Xiaolu⁷,Yang Zhenfan⁸,Jiang Haiyi⁹,Yang James Chih-Hsin¹⁰

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;

2. Seoul National University Hospital, Seoul, South Korea;

3. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of;

4. National Taiwan University Hospital, Taipei, Taiwan;

5. Global Medicine Development, AstraZeneca, Alderly Park, United Kingdom;

6. Early Clinical Development, AstraZeneca, Alderly Park, United Kingdom;

7. Innovation Center China, Innovative Medicines & Early Development, Shanghai, China;

8. Innovation Center China, Innovative Medicines & Early Development, AstraZeneca, Shanghai, China;

9. AstraZeneca China, Shanghai, China;

10. National Taiwan University, Taipei, Taiwan;

Publisher

American Society of Clinical Oncology (ASCO)

Subject